Article Text

Download PDFPDF
Gemfibrozil reduced the risk for coronary events in men with coronary artery disease and low levels of high density lipoprotein cholesterol

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 QUESTION: Is gemfibrozil effective for secondary prevention of coronary artery disease (CAD) events in men with low levels of both high density lipoprotein (HDL) and low density lipoprotein (LDL) cholesterol?


Randomised {allocation concealed*}, blinded (patients, outcome assessors, and study personnel),* placebo controlled trial with median follow up of 5.1 years (Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial [VA-HIT]).


20 Veterans Affairs medical centres in the United States.


2531 men who were <74 years of age (mean age 64 y); had a documented history of CAD; had no serious comorbid conditions; and had an HDL cholesterol level ≤40 mg/dl (1.0 mmol/l), an LDL cholesterol level ≤140 mg/dl (3.6 mmol/l), and a triglyceride level ≤300 mg/dl …

View Full Text


  • Sources of funding: Veterans Affairs Office of Research and Development and Parke-Davis.

  • For correspondence: Dr HB Rubins, Section of General Internal Medicine (111O), Veterans Affairs Medical Center, Minneapolis, MN 55417, USA. Fax +1 612 725 2118.

  • * See glossary.

  • Information provided by author.